CytomX Therapeutics (CTMX) Non-Current Assets (2014 - 2026)
CytomX Therapeutics' (CTMX) quarterly Non-Current Assets came in at $6.3 million in Q1 2026, down 47.24% YoY from $11.9 million in Q1 2025, and down 18.09% on a QoQ basis from $7.6 million in Q4 2025.
CytomX Therapeutics (CTMX) Non-Current Assets (2014 - 2026) Analysis & Trends
CytomX Therapeutics (CTMX) has 13 years of Non-Current Assets data on file, last reported at $6.3 million in Q1 2026.
- Quarterly Non-Current Assets fell 47.24% year-over-year to $6.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $33.4 million (down 40.43% YoY) and the FY2025 annual result came in at $7.6 million, down 42.21% from the prior year.
- Non-Current Assets retreated to $6.3 million in Q1 2026, from $7.6 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $28.4 million in Q1 2022 to a low of $6.3 million in Q1 2026.
- A 5-year average of $17.4 million and a median of $17.4 million in 2024 frame the typical range for Non-Current Assets.
- The widest YoY moves for Non-Current Assets: up 16.89% in 2022, down 79.87% in 2022.
- Tracing CTMX's Non-Current Assets over 5 years: stood at $23.8 million in 2022, then retreated by 20.74% to $18.9 million in 2023, then retreated by 29.85% to $13.2 million in 2024, then sank by 42.21% to $7.6 million in 2025, then retreated by 18.09% to $6.3 million in 2026.
- The last three Non-Current Assets figures came in at $6.3 million (Q1 2026), $7.6 million (Q4 2025), and $9.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | CytomX Therapeutics | 732.14 Mn | 401.86 Mn | - | 8.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.07 Mn |
| Mar 31, 2026 | 6.26 Mn |
| Dec 31, 2025 | 7.65 Mn |
| Sep 30, 2025 | 9.04 Mn |
| Jun 30, 2025 | 10.44 Mn |
| Mar 31, 2025 | 11.87 Mn |
| Dec 31, 2024 | 13.23 Mn |
| Sep 30, 2024 | 14.80 Mn |
| Jun 30, 2024 | 16.14 Mn |
| Mar 31, 2024 | 17.44 Mn |
| Dec 31, 2023 | 18.86 Mn |
| Sep 30, 2023 | 19.96 Mn |
| Jun 30, 2023 | 21.38 Mn |
| Mar 31, 2023 | 22.35 Mn |
| Dec 31, 2022 | 23.79 Mn |
| Sep 30, 2022 | 26.21 Mn |
| Jun 30, 2022 | 27.32 Mn |
| Mar 31, 2022 | 28.38 Mn |
| Dec 31, 2021 | 29.11 Mn |
| Sep 30, 2021 | 130.24 Mn |